Printer Friendly

CANDELA LASER'S NEW LASER WORKSTATION TO DIAGNOSE AND TREAT LEADING CAUSE OF BLINDNESS (Product Announcement)

 CANDELA LASER'S NEW LASER WORKSTATION TO DIAGNOSE AND TREAT
 LEADING CAUSE OF BLINDNESS
 WAYLAND, Mass., Feb. 7 /PRNewswire/ -- Candela Laser Corporation (NASDAQ: CLZR) today announced plans to market a diagnostic and treatment workstation to halt the advance of several eye diseases including age-related macular degeneration (AMD). Neovascular AMD is the leading cause of blindness in the over-50 age group affecting over 1 million people in the USA alone. The disease is characterized by an increasing dark or blind spot at the point of focus, eliminating the ability to read, drive automobiles or perform other common functions.
 WHO: --John Pavlic, chief executive officer,
 Candela Laser Corporation, Wayland, Mass.
 --Ann Eckert, director of marketing
 formerly Group Product Director-Ophthalmology
 Candela Laser Corporation, Wayland, Mass.
 --Carmen A. Puliafito, M.D., professor and chairman
 Department of Ophthalmology
 Tufts University School of Medicine
 New England Eye Center, Boston
 WHAT: A new laser system that halts the advance of several
 leading causes of blindness. The AMD Workstation,
 comprised of Candela's new Choriographer(tm) diagnostic
 unit and DioLaser(tm) treatment unit, enables eye doctors
 (ophthalmologists) to more easily see and more safely
 treat frequently undetectable membranes often associated
 with neovascular AMD. It provides the potential to
 preserve a greater degree of vision than is possible
 with existing treatments.
 WHERE: Wayland, Mass.
 WHEN: The laser workstation was made commercially available
 with recent Federal Food and Drug Administration (FDA)
 clearance of Candela's retinal fundus camera. The
 company is now integrating this camera with its previously
 FDA-cleared diode photocoagulator to provide improved
 diagnosis and treatment of a variety of retinal and
 choroidal diseases including the often devastating
 neovascular form of age-related macular degeneration.
 Shipments of the new laser workstation will begin in
 the spring of 1992.
 WHY: This new laser workstation, the first of four planned
 ophthalmology products from Candela, is believed to
 be the most technologically advanced system available
 to retinal specialists. This development is good news
 for over 1 million people in the U.S.A. alone who suffer
 from neovascular AMD.
 FACTS: Age-Related Macular Degeneration (AMD) is a disease characterized by the proliferation of new blood vessels directly behind the retina. The vessels in the most acute form proliferate under the central part of the retina called the macula, lifting it. In time, this part of the retina will become non-functional, creating a dark or blind spot. The macula controls central vision and permits reading, driving and all other activities requiring direct focus. Patients suffering from neovascular AMD in its final stages are legally blind, retaining only a part of their peripheral vision.
 ---
 NOTE: Fact sheet on the condition and laser are available.
 -0- 2/7/92
 /CONTACT: Drew Hall of Brodeur & Partners, 617-894-0003, for Candela Laser/
 (CLZR) CO: Candela Laser Corporation ST: Massachusetts IN: MTC SU: PDT


TM-SH -- NE005 -- 7797 02/07/92 13:15 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Article Type:Product Announcement
Date:Feb 7, 1992
Words:469
Previous Article:NEW ACHIEVA GAINS POPULARITY NATIONWIDE
Next Article:RECORD GAS BURN AT NYPA'S POLETTI PROJECT
Topics:


Related Articles
PHOENIX LASER SYSTEMS INC. SHIPS SURGICAL LASER WORKSTATION FOR GLAUCOMA TRIALS
NEW TATULAZR OFFERS SAFER REMOVAL OF TATTOOS
Candela expands skin laser product line.
Candela Says FDA Cleared New, Double-Powered Version of Innovative Dual Laser for Skin Resurfacing & Treating Facial Veins.
Clickmed Corporation Announces a Low Cost Generic Cryogen Replacement for Candela (CLZR) Lasers.
CANDELA SHATTERS REVENUE/PROFIT RECORDS IN FINAL QTR OF 1999.
FDA Approves Laser for Treatment of Facial Acne; Effects of Acne Are More Than Skin Deep ... Most Commonly Diagnosed Skin Disorder in U.S. Can Lead...
New Study: Smoothbeam(R) Laser Provides Long-Term Acne Solution.
Ellex Gains US FDA Approval for 30XL Laser Slit Lamp.
Studies Highlight A Revolutionary New Method of Treating Post-Operative Bruising.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters